Dr. Joshua Zeidner is an Associate Professor of Medicine at the University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, where he is the Section Chief of Leukemia Research, Associate Chief of Research, and the inaugural Director of Clinical Cancer Research, Commercial Integration. Dr. Zeidner’s research focuses on drug development, early-phase clinical trials, and innovative therapeutic strategies in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with a particular interest in the development of novel targeted therapeutic approaches such as menin inhibitors, immunotherapeutic approaches, and therapies targeted toward differentiation and apoptotic pathways. He has designed multiple Phase I–II studies in AML and oversees a robust clinical research program in Leukemia at the University of North Carolina.